Cingulate Inc. (NASDAQ:CINGW – Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 864 shares, a decline of 35.2% from the September 15th total of 1,333 shares. Based on an average trading volume of 3,292 shares, the days-to-cover ratio is currently 0.3 days.
Cingulate Stock Up 74.7%
Shares of Cingulate stock opened at $0.01 on Friday. Cingulate has a 52-week low of $0.00 and a 52-week high of $0.12. The company has a fifty day moving average of $0.01 and a 200-day moving average of $0.02.
About Cingulate
Cingulate Inc is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders. The company is focused on its Precision Timed Release (PTR) drug-delivery platform, which is designed to deliver multiple doses of medication at specific times from a single dosage form.
Cingulate’s lead program, CTx-1301, is an investigational extended-release formulation of dexmethylphenidate intended to treat attention-deficit/hyperactivity disorder (ADHD). The company has also pursued CTx-1302, an investigational treatment candidate for anxiety disorders.
Further Reading
- Five stocks we like better than Cingulate
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
